



FOR IMMEDIATE RELEASE

Clearbridge Health Raises S\$1.98 Million From Placement; Backed by High-Profile Investors to Fuel Strategic Growth

- Prominent funds Asdew Acquisitions, Azure Capital and veteran investor Ramesh Chandiramani are among placees for the Placement
- Capital injection follows major balance sheet recapitalisation, proposed creation cellular banking of adult immune cells and the US\$330M acquisition of biopharma innovator Elpis, signalling new era of expansion
- Placement of 990,000,000 new ordinary shares at S\$0.002 each has been fully taken up
- Raised gross proceeds of S\$1,980,000, which will be used primarily for general working capital purposes

SINGAPORE, 18 August 2025 – SGX Catalist-listed Clearbridge Health Limited (1H3) ("Clearbridge Health", the "Company", and together with its subsidiaries, the "Group") is pleased to announce that it has successfully completed a placement of 990,000,000 new ordinary shares ("**Placement Shares**") at an issue price of S\$0.002 per Placement Share, raising gross proceeds of S\$1,980,000. The placement drew strong interest from notable investors, including prominent funds Asdew Acquisitions and Azure Capital, as well as veteran investor Ramesh Chandiramani.

The Company has also issued 659,999,996 free warrants on the basis of two warrants for every three Placement Shares subscribed.

The gross proceeds will be used primarily for general working capital purposes, to address immediate business needs, and to maintain the Group's competitiveness. The funds will also be used to capitalise on business opportunities that align with the Group's strategic objectives and provide long-term growth and value for shareholders.

Mr. Terence Wong, CEO of Azure Capital also commented: ***"This placement reflects our confidence in Jeremy's leadership and Clearbridge Health's strategic direction. The company's transformation into a debt-free entity, coupled with promising future opportunities, presents a compelling investment proposition."***



Commenting on the placement, Mr. Jeremy Yee, Executive Director and CEO of Clearbridge Health, said: ***"This successful placement reflects strong investor confidence in our business model and growth trajectory. The additional capital will bolster our financial resources, enabling us to pursue strategic opportunities with greater agility as we execute our long-term vision."***

Building on a Fortified Foundation: A Debt-Free, Agile Company

The successful placement is the latest strategic move in a comprehensive recapitalisation exercise designed to create a robust and resilient financial foundation for the Company. In recent months, Clearbridge Health has systematically de-risked its balance sheet through a series of decisive actions:

- A completed rights issue at S\$0.002 per share and a share placement at S\$0.0031 per share
- Full repayment of all outstanding bank borrowings
- Conversion of S\$3.5 million in convertible bonds at S\$0.0031 per share, a move also supported by Executive Director and CEO, Mr. Jeremy Yee, who converted his own bond holdings into equity

Following the completion of this exercise, Clearbridge Health is now entirely equity-financed. This debt-free status not only provides significant financial stability but also grants the management the agility and flexibility to seize strategic opportunities without the constraints of debt covenants, positioning the Company for sustainable, long-term value creation for its shareholders.

Following the completion of the Placement, the total number of issued shares of the Company has increased from 3,305,820,825 shares to 4,295,820,825 shares.

UOB Kay Hian Private Limited is the placement agent.

Accelerating Future Growth: The Proposed Elpis Biopharmaceuticals Acquisition

The newly raised funds are earmarked primarily for general working capital, which will be instrumental in supporting the Company's next major strategic leap: the creation of adult immune cellular banking and the proposed acquisition of Elpis Biopharmaceuticals ("**Elpis**"). On 28 April 2025, Clearbridge Health entered into a binding term sheet with Elpis for this transformative transaction. Further on 6 June 2025, the Company entered into a strategic alliance agreement with Guangdong Amoreneg Medicine Research and Development Co. Ltd. ("**GAMRD**"), pursuant to which, amongst others, the Company intends to appoint GAMRD as a consultant to provide advisory services in relation to the Group's proposed establishment of a peripheral blood mononuclear cells processing and cryogenic storage facility. The Group has since incorporated companies in both Singapore and Hong Kong to prepare the launch of the adult immune cellular banking business.

The creation of adult cellular banking is a necessary component of any autologous immunotherapy regime and serves as a symbiotic revenue generating function not only to Elpis' drug discovery platform but as an autologous source of immune cells worldwide, especially in Asia, to support the increasing number of approved and clinical trial CAR-T and



other cellular therapies. Elpis is a pre-clinical stage biopharmaceutical company at the forefront of developing next-generation biological and cellular therapeutics for difficult-to-treat cancers. The proposed acquisition represents a significant expansion of Clearbridge Health's capabilities, moving it further up the value chain in the high-growth oncology market.

Key terms of the proposed acquisition include:

- Elpis has an indicative value of US\$330 million (approximately S\$421 million), subject to confirmation by an independent valuer, due diligence and approval from the Company's shareholders;
- The acquisition will be settled through the issuance of new ordinary shares in Clearbridge Health, aligning the interests of Elpis's stakeholders with existing shareholders. These consideration shares will be subject to a stringent moratorium period of up to 36 months, ensuring long-term commitment.

The capital from the placement will provide the necessary resources to maintain operational momentum and ensure the Group is well-positioned to meet all conditions precedent for the successful completion of the acquisition, while continuing to explore other synergistic business opportunities.

- End -

This press release is to be read in conjunction with the Company's announcement released on 28 April 2025, 6 June 2025, 4 August 2025 and 18 August 2025, which can be downloaded via www.sgx.com.

About Clearbridge Health Limited

Clearbridge Health Limited is a healthcare company with a focus on the delivery of precision medicine in Asia. The Group's vision is to empower clinicians and healthcare professionals to make more reliable and accurate diagnoses, provide insights to disease management and tailor personalised prevention and timely treatment programmes for patients. The Group's technology agnostic approach allows it to adopt the most appropriate technology in each segment of its business and the products and/or services it offers. The Group's business comprises (a) provision of laboratory testing services; (b) ownership and operation of medical clinics/centres; and (c) strategic equity participation in precision medical technology companies which complement its business objectives.

For more information, please visit <http://www.clearbridgehealth.com>

This press release has been reviewed by the Company's sponsor, UOB Kay Hian Private Limited (the "Sponsor").



This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited (the “SGX-ST”) and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr Lance Tan, Senior Vice President, at 83 Clemenceau Avenue, #10-01 UE Square, Singapore 239920, telephone (65) 6590 6881.